Under the agreement, the two companies will develop diagnostic products that incorporate Fujirebio Diagnostics’s cancer biomarkers for use on Becton, Dickinson and Company’s (BD) multiplex testing platform. The initial products will be directed to the ovarian cancer biomarker, HE4, which is FDA-cleared for monitoring the progression or recurrence of epithelial ovarian cancer.
Fujirebio Diagnostics also granted BD, through its BD Diagnostics – TriPath platform, access to its other cancer biomarkers for inclusion in future multiplex diagnostic products.
Paul Touhey, president and CEO of Fujirebio Diagnostics, said: “This alliance with BD is an excellent strategic fit for Fujirebio Diagnostics’s business. It will increase the use of HE4 as a tool in monitoring ovarian cancer and allow Fujirebio Diagnostics to utilize its expertise in cancer biomarker development and manufacturing, providing to physicians additional tools to manage cancer patients.”